Dialysis

 

17 things we learned at HBI 2023: Our key insights and takeaways

Our annual conference took place earlier this week in London. Over a jam-packed three days of HBI 2023, an impressive array of delegates from across Europe and beyond gathered in the heart of London and shared their insights into the myriad challenges and abundant opportunities the sector faces, and offered their views on how some of them might be addressed. Here are some of our key takeaways.
June 23, 2023

Is there any need to panic over South African NHI?

Last week HBI reported on the South African parliament approving a national / statutory health insurance scheme, which would bring universal healthcare to the rainbow nation at the expense of private providers. HBI speaks to a South African operator to find out how this may affect them.
June 23, 2023

Ukraine Minister of Health Recovery to speak at HBI 2023

Ukraine has big plans to leverage the for-profit sector to rebuild its shattered health care system after the war. Oleksii Iaremenko, Head of Health Recovery at the Ukraine Ministry of Health is speaking at HBI 2023, June 19-21. Meanwhile we talk to fellow panelist Mark Hellowell, an academic at the University of Edinburgh who with the EBRD is sitting alongside Iaremenko on the Ukraine panel.
June 16, 2023

Top destinations for holiday dialysis

In its recent ESG report, multinational dialysis firm Diaverum revealed the top 10 countries in Europe and internationally where patients use the group's holiday dialysis treatment.
May 18, 2023

Mubadala-backed M42 buying Diaverum “for $2bn+”

Swedish multinational dialysis firm Diaverum is being bought by M42, a joint venture between Abu Dhabi sovereign wealth fund Mubadala Investment Co and AI firm G42, for a reported $2bn-$2.5bn. Diaverum’s CEO tells HBI the deal offers further opportunities to develop its digital strategies, and international expansion. 
April 19, 2023

Diaverum deal: An analysis

Last week the news broke that Abu Dhabi sovereign wealth fund Mubadala Investment Co might be set to buy Swedish multinational dialysis firm Diaverum for a reported $2.5bn. HBI speaks to an operator source who thinks this would be a good price for the seller - and hears why some investors are switched off by dialysis.
April 6, 2023

Key themes and takeaways from the IFC’s Emerging Markets conference

Last month, thought leaders from private healthcare systems across the globe gathered in Cape Town, South Africa, to network, share their findings, and consider how emerging markets can become more resilient. HBI was there, and these are our key themes and takeaways.
March 3, 2023

Shareholders unconvinced by “future Fresenius”

Michael Sen, CEO of multinational healthcare conglomerate Fresenius, finally set out his long-awaited plan for a “Future Fresenius” at the group’s end of year results this week. But is it a radical shake up, or PR puff? HBI investigates why shareholders appear unconvinced.
February 24, 2023
Newer posts
Older posts

Our Services

Company

Resources

Log in
Register
Log in
Register

Our Services

Company

Resources

Find Us